Editor's Note: This post originally appeared on the Hospital for Special Surgery's eAcademy.
Stephen Paget, MD: I'm Steve Paget, the physician-in-chief emeritus at the Hospital for Special Surgery in New York City. We're here today to discuss comorbidities in inflammatory joint diseases.
Sergio Schwartzman, MD: I'm Sergio Schwartzman, an associate professor here at the Hospital for Special Surgery.
Dr Paget: Sergio is quite expert in a few areas of inflammatory joint disease that I think are really important to discuss today. His knowledge spans the breadth of rheumatoid arthritis (RA), spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, et cetera.
Maybe 15 or 20 years ago, I and other scientists here convened a group of investigators to try and decide whether atherosclerosis was premature in people with RA and lupus. We found that the risk for this is actually quite high. There seems to be a spillover effect of the proinflammatory cytokines on the endothelial cells to the point where, I believe, premature atherosclerosis is an extra-articular manifestation of the disease.
What are your thoughts about that, Sergio, and what to do about it?
Extra-articular Manifestation vs Comorbidity
Dr Schwartzman: The first question is what is an extra-articular manifestation of the disease, and what is the comorbidity.
Hand and Wrist Surgery in Rheumatoid Arthritis
Rheumatoid Arthritis (RA)
Rheumatoid Arthritis Clinical Practice Guidelines (JCR, 2022)
COMMENTARY
In RA, Treating Heart Disease and Other Comorbidities
Stephen Paget, MD; Sergio Schwartzman, MD
DisclosuresNovember 30, 2016
Editorial Collaboration
Medscape &
Editor's Note: This post originally appeared on the Hospital for Special Surgery's eAcademy.
Stephen Paget, MD: I'm Steve Paget, the physician-in-chief emeritus at the Hospital for Special Surgery in New York City. We're here today to discuss comorbidities in inflammatory joint diseases.
Sergio Schwartzman, MD: I'm Sergio Schwartzman, an associate professor here at the Hospital for Special Surgery.
Dr Paget: Sergio is quite expert in a few areas of inflammatory joint disease that I think are really important to discuss today. His knowledge spans the breadth of rheumatoid arthritis (RA), spondyloarthritis, psoriatic arthritis, ankylosing spondylitis, et cetera.
Maybe 15 or 20 years ago, I and other scientists here convened a group of investigators to try and decide whether atherosclerosis was premature in people with RA and lupus. We found that the risk for this is actually quite high. There seems to be a spillover effect of the proinflammatory cytokines on the endothelial cells to the point where, I believe, premature atherosclerosis is an extra-articular manifestation of the disease.
What are your thoughts about that, Sergio, and what to do about it?
Extra-articular Manifestation vs Comorbidity
Dr Schwartzman: The first question is what is an extra-articular manifestation of the disease, and what is the comorbidity.
Hospital for Special Surgery eAcademy © 2016 Hospital for Special Surgery
Cite this: In RA, Treating Heart Disease and Other Comorbidities - Medscape - Nov 30, 2016.
Tables
References
Authors and Disclosures
Authors and Disclosures
Author
Stephen A. Paget, MD, FACP, FACR
Rheumatologist, Physician-in-Chief Emeritus, Hospital for Special Surgery, New York, New York
Disclosure: Stephen Paget, MD, FACP, FACR, has disclosed the following financial relevant financial relationships:
Serve(d) as a consultant, writer and speaker: Medscape
Sergio Schwartzman, MD
Associate Attending Physician, Hospital for Special Surgery, New York, New York
Disclosure: Sergio Schwartzman, MD, has disclosed the following financial relevant financial relationships:
Serve(d) as a speaker, a consultant or a member of a speakers bureau for: AbbVie, Amgen, Genentech, Hospira, Pfizer, UCB Pharmaceuticals, Xian Janssen Pharmaceuticals, Ltd., Lilly Regeneron Sanofi